Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS) today announced the launch of a registered direct offering to purchase 1,333,334 units consisting of one American Depositary Share (ADS) or one prefunded warrant giving right to one ADS and one warrant each.
At a purchase price of $2.85 per unit, each ADS will give the right to receive one hundred new ordinary shares of the Company. The prefunded warrants are subscribed at a price of $2.84 and will have an immediate exercise price of $0.01 per ADS which will expire in ten years.
The ordinary warrants, which become exercisable immediately, will have an exercise price of $3.00 per ADS which expire in three years. This exciting development provides an opportunity for those wishing to invest in the Company.
The Company is pleased to announce plans to raise $3.8 million through an equity offering set to close on July 21, 2023, provided all conditions are met. The raised funds will be allocated toward ongoing research and development, clinical trials, and other working capital and general corporate initiatives. We invite you to be part of this venture and support our ambitious journey!
H.C. Wainwright & Co. has the esteemed honor of serving as the exclusive placement agent for this exciting offering. They are proud to help facilitate the realization of this opportunity and look forward to its successful execution.
The Company is delighted to announce the offering of its American Depository Shares (ADSs) and pre-funded warrants (and the underlying ADSs) through a “shelf” registration statement on Form F-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on April 21, 2023 and declared effective on May 1, 2023.
The prospectus, including the prospectus supplement, forming part of the effective registration statement, will provide more details regarding these unique offerings. Don’t miss out on this amazing opportunity to invest and experience the potential rewards of the future!
The ordinary warrants and the ADSs underlying them are now made available through a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D.
Unfortunately, they have not been registered under the Securities Act or associated state securities laws, meaning they cannot be sold or offered in the United States without an effective registration statement or applicable exemption.
About BIOPHYTIS
Biophytis SA is a pioneering biotechnology company with a focus on the development of innovative drug treatments for age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is a small molecule with promising results in the treatment of sarcopenia, Duchenne muscular dystrophy, and Covid-19.
We are running several clinical trials, including a phase 3 study in sarcopenia (the SARA project), a phase 2-3 clinical trial in Covid-19 (the COVA6 project), and a pediatric formulation for Duchenne muscular dystrophy (the MYODA project).
Our offices are located in Paris, France, and Cambridge, Massachusetts, and our shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and Nasdaq Capital Market.